Frontage Holdings Corporation
FGHQF
Other OTC0.11
USD
- -
- -
ISIN
KYG3679P1019
Return %
Stock
S&P500
1Y
8.91
26.53
3Y
-66.32
76.60
5Y
-77.56
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Zhongping Lin
- Full Time Employees
- 1,560
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 700 Pennsylvania Drive Exton PA United States of America 19341
- IPO Date
- Apr 14, 2020
- Website
- frontagelab.com
- Similar Companies
- Business
- Frontage Holdings Corporation is a contract research organization (CRO) providing integrated research, development, and laboratory services primarily to the pharmaceutical, biotechnology, and medical device industries. The company offers a comprehensive suite of services including drug metabolism and pharmacokinetics (DMPK); bioanalytical services; analytical chemistry; stability storage and testing; CMC (chemistry, manufacturing, and controls) product development and manufacturing; clinical trial support including central laboratory and clinical pharmacology services; microbiology and toxicology testing; formulation development; and GMP manufacturing of complex dosage forms such as injectables, ophthalmic products, and nasal preparations. Frontage serves global markets with operations principally in the United States, China, Canada, and Europe, targeting multinational pharmaceutical companies, biotech firms, and research institutions. Founded in 2001 and headquartered in Exton, Pennsylvania, the company operates through several subsidiaries including Frontage Laboratories, Inc. and Frontage Europe S.r.l. In recent developments, Frontage has significantly expanded its capabilities and geographic reach. Notably, in 2023, Frontage completed the acquisition of Nucro-Technics Inc., enhancing its analytical chemistry, microbiology, toxicology, and bioanalytical service offerings and strengthening its presence in Canada. In 2024, the company acquired Accelera S.r.l.'s bioanalytical and DMPK businesses based in Italy, broadening its European footprint and capabilities in oncology and drug research. Also in 2025, Frontage announced the acquisition of Shanghai Guanhe Pharmaceutical Technology Co., Ltd. for RMB 270 million to bolster its clinical research laboratory services and expand its central laboratory operations in China and the Asia-Pacific region. Complementing these acquisitions, Frontage invested in expanding its life sciences facilities in North America and China, including over 46,300 square feet of new laboratory and manufacturing space in Exton, Pennsylvania, and doubling its Process Scale-Up Hub laboratory space in Wuhan. The company also enhanced its CMC product development with new GMP ophthalmic drug manufacturing lines and advanced formulation capabilities. Strategic partnerships have been a focus for Frontage's growth. In 2025, the company entered into a memorandum of understanding (MOU) with GCCL to jointly support clinical trial services in the U.S. and APAC regions, aiming to strengthen its clinical trial support system in Asia-Pacific. Additionally, Frontage partnered with EPNextS Group to advance collaborative business development activities in Japan and the United States, emphasizing clinical trial solutions and site management services with a focus on Japanese client needs. Frontage Holdings operates within the pharmaceutical services and contract research organization industries, providing science-driven research and development services for drug discovery, development, and commercialization. It serves a wide range of clients including multinational pharmaceutical corporations, biotech companies, and clinical research organizations with geographic operations spanning North America, Asia-Pacific, and Europe. This combination of expanding global footprint, diversified service offerings across drug development stages, and strategic alliances positions Frontage Holdings Corporation as a comprehensive, integrated CRO with capabilities from early-stage research through clinical trial execution and commercial drug manufacturing. The company’s recent acquisitions and facility expansions reflect an ongoing strategic emphasis on enhancing laboratory and manufacturing capacities to meet growing client demand for complex and regulated drug development services.